translational-medicine-and-oncologists-meet-2016_posters

17 / 18

Volume 6, Issue 4(Suppl) Transl Med 2016
ISSN: 2161-1025, an open access journal
Page 77
conferenceseries.com
Translation Medicine & World Oncologists 2016
November 28-30, 2016
Translational Medicine and Oncologists Meet
November 28-30, 2016 San Francisco, USA
14th Annual Conference on
An update on methods for cryopreservation and thawing of hemopoietic stem cells
Lucilla Lecchi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
This presentation will focus on a number of variables related to stem cells cryopreservation procedures of minimally manipulated
products containing allogeneic or autologous hemopoietic progenitor cells (HPC) used for transplantation. The issues includes:
regulations and standards, processing, process validation and qualification, volume reduction, cell concentration, volume, freezing,
storage, cooling rate, warming events, quarantine, cross contamination during storage and thawing. New approaches of processing
were developed such as automatic devices for volume reduction and high cell concentration in the frozen product. DMSO at
10% final concentration is still the most used cryo-protectant for HPC cryopreservation. Although controlled rate freezing is the
recommended method for HPC cryopreservation, alternative methods may be used. Last generation vapor storage vessels ensure
temperature stability better than older tanks and may reduce risks of cross-contamination. Finally, advantages and disadvantages of
thawing procedures carried out at patient’s bedside or in the laboratory will be discussed.
Transl Med 2016, 6:4(Suppl)
DCIS in BRCA1 and BRCA2 mutation carriers: Prevalence, phenotype and expression of
oncodrivers C-MET and HER3
Rachel L Yang, Rosemarie Mick, Kathreen Lee, Holly L Graves, Katherine L Nathanson, Susan M Domchek, Rachel R Kelz, Paul J Zhang and Brian J Czerniecki
University of Pennsylvania, USA
Background:Studies report conflicting evidence regarding the existence of a (ductal carcinoma in situ) DCIS-associated premalignant
pathway in BRCA mutation carriers. We aimed to examine the prevalence, phenotype and expression of oncodrivers in pure DCIS
(pDCIS) and invasive breast cancer with concurrent DCIS (IBC+DCIS) in mutation carriers.
Methods: A cohort of BRCA1 and BRCA2 mutation carriers >18 years old who underwent surgery for breast cancer at an academic
hospital (1992-2011) and had pathology available for review were included for study. Invasive breast cancer (IBC) and DCIS were
stained for ER, PR, HER1, HER2, and HER3, and C-MET. DCIS prevalence was evaluated. Correlation of IBC and DCIS phenotypes
was evaluated in patients with IBC+DCIS. DCIS and IBC expression of tumor markers were examined by BRCA mutation.
Results: We identified 114 breast tumors. Of all BRCA1-associated tumors, 21.1% were pDCIS and 63.4% were IBC+DCIS. Of
all BRCA2-associated tumors, 23.3% were pDCIS and 60.5% were IBC+DCIS. In BRCA1 and BRCA2 mutation carriers with
IBC+DCIS, there was a significant correlation in ER, PR, and HER3 expression between the DCIS and IBC components. Most
BRCA1-associated DCIS did not express ER, PR or HER2, while most BRCA2-associated DCIS expressed ER and PR. BRCA1- as
well as BRCA2-associated DCIS had expression of HER3 and C-MET.
Conclusions: The majority of BRCA-associated tumors had DCIS present. Concordance of DCIS and IBC phenotypes was high,
arguing for the existence of a DCIS-associated premalignant pathway. Oncodrivers HER3 and C-MET were expressed in the DCIS
of mutation carriers, suggesting an opportunity for prevention strategies.